Tier 3 — preclinical

Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man

Y Tomono, J Hasegawa, T Seki, K Motegi, N Morishita
International Journal of Clinical Pharmacology, Therapy and Toxicology 1986 24(10):536-541

Bibliography

PubMed
PMID 3781673

Study snapshot

DesignHuman single-dose pharmacokinetic study
ModelHealthy adult men
Sample16
Intervention100 mg oral deuterium-labelled CoQ10 (d5-CoQ10)
DurationSingle-dose plasma pharmacokinetic follow-up
EndpointsTime to peak plasma concentration; Peak plasma concentration; Terminal half-life; Concentration-time pattern

What the study showed, in plain terms

Sixteen healthy men received a single 100 mg oral dose of deuterium-labelled CoQ10 so researchers could characterize its human plasma pharmacokinetics.

Average peak plasma concentration occurred several hours after dosing and the terminal half-life was roughly 33 hours, showing that CoQ10 behaves very differently from a rapidly cleared stimulant.

Key findings

Mean time to peak plasma concentration was 6.5 ± 1.5 hours.

Mean terminal half-life was 33.19 ± 5.32 hours.

A second plasma peak around 24 hours was observed in most participants.

What this study can and cannot tell us

The study was small, included only healthy men, used an older formulation and analytical approach, and measured pharmacokinetics rather than symptoms or clinical outcomes.

It did not compare morning with evening dosing, so it cannot establish an ideal clock time for taking CoQ10.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology